Association between the hMSH2 IVS12-6 T>C polymorphism and cancer risk: A meta-analysis

Wu,Song; Chen,Jingyu; Ji,Yong; Liu,Yuxin; Gao,Lu; Chen,Guoqiang; Shen,Kai; Huang,Bin

doi:10.3892/etm.2011.336

Association between the hMSH2 IVS12-6 T>C polymorphism and cancer risk: A meta-analysis

Authors:
- Song Wu
- Jingyu Chen
- Yong Ji
- Yuxin Liu
- Lu Gao
- Guoqiang Chen
- Kai Shen
- Bin Huang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Affiliated Jiangyin People's Hospital of Southeast University Medical College, Jiangyin, Jiangsu, P.R. China, Department of Cardiothoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, P.R. China, Department of Nutrition and Food Hygiene, Nanjing Medical University, Nanjing, P.R. China
Published online on: August 16, 2011 https://doi.org/10.3892/etm.2011.336
Pages: 1193-1198

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abstract. The hMSH2 gene, a member of the mismatch repair (MMR) pathway, plays a key role in the maintenance of genomic integrity. The common sequence variation in hMSH2, IVS12-6 T>C, has been implicated in cancer risk. However, the results of published studies on this polymorphism remain conflicting. Hence, we conducted a meta-analysis to clarify the role of the hMSH2 IVS12-6 T>C polymorphism in cancer. We performed a comprehensive literature search updated to March 2011 of studies on the associations between the hMSH2 IVS12-6 T>C polymorphism and cancer risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. Thirteen studies involving 7,527 patients and 8,762 control subjects were included in this meta-analysis. The overall results indicated no major influence of the polymorphism on cancer risk. However, stratified analysis by cancer types showed that the hMSH2 IVS12-6 polymorphism increased the risk for non-Hodgkin's lymphomas (heterozygote comparison: OR=1.62; 95% CI 1.06-2.47). When stratified by the source of controls, significant associations were observed in hospital-based populations (heterozygote comparison: OR=1.28; 95% CI 1.02-1.61). These results indicate that the polymorphism of hMSH2, IVS12-6, may cause a different effect in different types of cancers. To draw more comprehensive conclusions, further prospective studies with larger numbers of participants worldwide are required to examine the associations between this polymorphism and cancer risk.

View Figures

View References

1	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
2	Schofield MJ and Hsieh P: DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol. 57:579–608. 2003. View Article : Google Scholar : PubMed/NCBI
3	Koessler T, Oestergaard MZ, Song H, et al: Common variants in mismatch repair genes and risk of colorectal cancer. Gut. 57:1097–1101. 2008. View Article : Google Scholar : PubMed/NCBI
4	Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD and Ishioka C: Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res. 67:4595–4604. 2007. View Article : Google Scholar : PubMed/NCBI
5	Kunkel TA and Erie DA: DNA mismatch repair. Annu Rev Biochem. 74:681–710. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kinzler KW and Vogelstein B: Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 386:7617631997. View Article : Google Scholar : PubMed/NCBI
7	Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
8	Kolodner RD: Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci. 20:397–401. 1995. View Article : Google Scholar : PubMed/NCBI
9	Modrich P and Lahue R: Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem. 65:101–133. 1996. View Article : Google Scholar : PubMed/NCBI
10	Demokan S, Suoglu Y, Ulusan M and Dalay N: Analysis of the hMSH2 gene variants in head and neck cancer. DNA Cell Biol. 29:449–457. 2010. View Article : Google Scholar : PubMed/NCBI
11	Goessl C, Plaschke J, Pistorius S, et al: An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. Eur J Cancer. 33:1869–1874. 1997. View Article : Google Scholar : PubMed/NCBI
12	Hishida A, Matsuo K, Hamajima N, et al: Polymorphism in the hMSH2 gene (gIVS 12-6T-->C) and risk of non-Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogenet. 147:71–74. 2003.PubMed/NCBI
13	Hsu HS, Lee IH, Hsu WH, Kao WT and Wang YC: Polymorphism in the hMSH2 gene (gISV12-6T > C) is a prognostic factor in non-small cell lung cancer. Lung Cancer. 58:123–130. 2007.PubMed/NCBI
14	Jung CY, Choi JE, Park JM, et al: Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 15:762–768. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kim JC, Roh SA, Koo KH, et al: Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. Fam Cancer. 3:129–137. 2004. View Article : Google Scholar
16	Paz-y-Mino C, Fiallo BF, Morillo SA, et al: Analysis of the polymorphism [gIVS12-6T > C] in the hMSH2 gene in lymphoma and leukemia. Leuk Lymphoma. 44:505–508. 2003.
17	Paz-y-Mino C, Perez JC, Fiallo BF and Leone PE: A polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet. 133:29–33. 2002.
18	Raptis S, Mrkonjic M, Green RC, et al: MLH1 −93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 99:463–474. 2007.
19	Song H, Ramus SJ, Quaye L, et al: Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis. 27:2235–2242. 2006. View Article : Google Scholar : PubMed/NCBI
20	Tulupova E, Kumar R, Hanova M, et al: Do polymorphisms and haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer? Mutat Res. 648:40–45. 2008. View Article : Google Scholar : PubMed/NCBI
21	Beiner ME, Rosen B, Fyles A, et al: Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev. 15:1636–1640. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bubb VJ, Curtis LJ, Cunningham C, et al: Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene. 12:2641–2649. 1996.PubMed/NCBI
23	Xia L, Shen W, Ritacca F, et al: A truncated hMSH2 transcript occurs as a common variant in the population: implications for genetic diagnosis. Cancer Res. 56:2289–2292. 1996.PubMed/NCBI
24	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
25	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
26	Chung DC and Rustgi AK: The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 138:560–570. 2003. View Article : Google Scholar : PubMed/NCBI
27	Rowley PT: Inherited susceptibility to colorectal cancer. Annu Rev Med. 56:539–554. 2005. View Article : Google Scholar : PubMed/NCBI
28	Lynch HT and de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 348:919–932. 2003. View Article : Google Scholar : PubMed/NCBI
29	Chen Y, Wang J, Fraig MM, et al: Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 61:4112–4121. 2001.PubMed/NCBI
30	Lax SF: Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 444:213–223. 2004. View Article : Google Scholar : PubMed/NCBI
31	Wilentz RE, Goggins M, Redston M, et al: Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 156:1641–1651. 2000. View Article : Google Scholar : PubMed/NCBI
32	Schneider BG, Bravo JC, Roa JC, et al: Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population. Int J Cancer. 89:444–452. 2000. View Article : Google Scholar : PubMed/NCBI
33	Beghelli S, de Manzoni G, Barbi S, et al: Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery. 139:347–356. 2006. View Article : Google Scholar : PubMed/NCBI
34	Lawes DA, SenGupta S and Boulos PB: The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol. 29:201–212. 2003. View Article : Google Scholar : PubMed/NCBI
35	Trojan J, Zeuzem S, Randolph A, et al: Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. 122:211–219. 2002. View Article : Google Scholar : PubMed/NCBI
36	Hutter P, Couturier A and Rey-Berthod C: Two common forms of the human MLH1 gene may be associated with functional differences. J Med Genet. 37:776–781. 2000. View Article : Google Scholar : PubMed/NCBI
37	Hutter P, Wijnen J, Rey-Berthod C, et al: An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1. J Med Genet. 39:323–327. 2002. View Article : Google Scholar : PubMed/NCBI
38	Smith TR, Levine EA, Freimanis RI, et al: Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis. 29:2132–2138. 2008. View Article : Google Scholar : PubMed/NCBI
39	Mrkonjic M, Raptis S, Green RC, et al: MSH2 118T>C and MSH6 159C>T promoter polymorphisms and the risk of colorectal cancer. Carcinogenesis. 28:2575–2580. 2007.
40	Lynch HT, Smyrk T and Lynch JF: Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from pedigree anecdote to molecular genetic confirmation. Oncology. 55:103–108. 1998. View Article : Google Scholar